

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高視醫療科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT

DISPOSABLE OPHTHALMIC TROCAR AND ACCESSORIES OBTAINED MEDICAL DEVICE REGISTRATION CERTIFICATE IN CHINA

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that Gaush Precision Ltd* (高視精密醫療器械(蘇州)有限公司) (“**Gaush Precision**”), a subsidiary of the Company, has recently obtained the medical device registration certificate for its “disposable ophthalmic trocar and accessories” from the Jiangsu Medical Products Administration.

In the backdrop of growing aging population and lifestyle change, age-related eye diseases and metabolism-related eye diseases have become increasingly prominent. Fundus diseases have now emerged as the leading cause of irreversible blindness in China. Currently, there are a total of over 40 million patients suffering from various fundus diseases in China, and this number also grows by more than 3 million new cases each year. Analysis of professional organizations indicates that in 2023, the volume of vitrectomy surgeries performed in China exceeded 500,000 cases, and this volume of surgeries is expected to increase year by year with the support of healthcare policies. With the accelerating urbanization and aging demographics, as well as the rising number of obesity and diabetes cases due to improved living standards, the incidence of fundus diseases has been increasing annually. Without intervention and treatment, fundus diseases carry the risk of blindness. Ocular conditions such as diabetic retinopathy and age-related macular degeneration may pose significant blindness risks to patients. Currently, the commonly used vitrectomy surgeries require the establishment of surgical instrument access through the sclera, 3mm-4mm posterior to the corneal limbus, using a disposable ophthalmic trocar.

The disposable ophthalmic trocar and accessories (Registration Certificate No.: Su Xie Zhu Zhun 20252161055) of Gaush Precision approved this time are mainly applicable for 23G/25G vitrectomy surgeries. Compared to similar products on the market, they ensure no scleral deformation during intraoperative puncture, and offer exceptional sharpness, excellent incision airtightness, minimal wound trauma, and faster postoperative wound healing and recovery.

This product is an original design and invention of Gaush Precision. The unique innovative technology combines a dual needle and blade design, featuring a gradual puncture process. When performing scleral incision punctures, it prevents scleral depression and maintains a consistent linear incision shape. The incision exhibits excellent sealing properties, ensuring the product's sharpness and optimal incision closure.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, June 16, 2025

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.

* *For identification purpose only*